[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337882-105":59,"doc-detail-337882-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","pi3kaktmtor-signaling-pathway-an-important-driver-and-therapeutic-target-in-triple-negative-breast-cancer","PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer","","Triple-negative breast cancer (TNBC) is a heterogeneous tumor defined by the lack of estrogen receptor (ER), progesterone receptor (PR), and HER2 expression, resulting in aggressive behavior, frequent metastasis, and limited effective treatments. The PI3K/AKT/mTOR pathway is commonly over-activated in human cancers and promotes TNBC growth, survival, proliferation, angiogenesis, and resistance. This review outlines TNBC-specific activation mechanisms, links activation to TNBC subtypes, and summarizes recent kinase-inhibitor clinical studies and key issues for therapeutic application.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/pi3kaktmtor-signaling-pathway-an-important-driver-and-therapeutic-target-in-triple-negative-breast-cancer/337882/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/pi3kaktmtor-signaling-pathway-an-important-driver-and-therapeutic-target-in-triple-negative-breast-cancer/337882.png","ImageObject",300,407,{"name":92,"@type":93},"Maeve","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":24},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes triple-negative breast cancer (TNBC) clinically challenging?","Question",{"text":112,"@type":113},"TNBC lacks ER, PR, and HER2, showing higher aggressiveness and a poor prognosis, with limited effective therapeutic strategies and frequent distant metastasis.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the PI3K/AKT/mTOR signaling pathway contribute to TNBC progression?",{"text":117,"@type":113},"Over-activation of PI3K/AKT/mTOR supports TNBC growth and survival, enhances proliferation and migration, and influences processes such as apoptosis inhibition, differentiation, and autophagy.",{"name":119,"@type":110,"acceptedAnswer":120},"Which regulators are mentioned as key controls of the PI3K pathway in TNBC?",{"text":121,"@type":113},"PTEN negatively regulates PI3K by dephosphorylating PIP3 to PIP2 and silencing AKT signaling; additional phosphatase regulation is also described, affecting pathway activation.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337882,1790336815,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":24,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909877438554,"https://ap-avatar.wpscdn.com/avatar/5600025385ad2bf12a7?_k=1778553567797529272","Breast Cancer (2024) 31:539–551  \n[https://doi.org/10.1007/s12282-024-01567-5](https://doi.org/10.1007/s12282-024-01567-5)  \nPI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple‑negative breast cancer  \nHuan‑ping Zhang1,2 · Rui‑yuan Jiang1,3 · Jia‑yu Zhu1,3 · Ke‑na Sun1,2 · Yuan Huang1 · Huan‑huan Zhou1 · Ya‑bing Zheng1 · Xiao‑jia Wang1  \nReceived: 12 October 2023 / Accepted: 10 March 2024 / Published online: 17 April 2024 © The Author(s) 2024  \nAbstract  \nTriple-negative breast cancer (TNBC) is a highly heterogeneous tumor lacking estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression. It has higher aggressiveness and metastasis than other subtypes, with limited effective therapeutic strategies, leading to a poor prognosis. The phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mechanistic target of rapamycin (mTOR) signaling pathway is prevalently over-activated in human cancers and contributes to breast cancer (BC) growth, survival, proliferation, and angiogenesis, which could bean interesting therapeutic target. This review summarizes the PI3K/AKT/mTOR signaling pathway activation mechanism in TNBC and discusses the relationship between its activation and various TNBC subtypes. We also report the latest clinical studies on kinase inhibitors related to this pathway for treating TNBC. Our review discusses the issues that need to be addressed in the clinical application of these inhibitors.  \nKeywords Triple-negative breast cancer · PI3K · AKT · PTEN · Targeted therapy  \nIntroduction  \nBreast cancer (BC) is the most common and life-threatening malignancy affecting women, with approximately 2.3 million new cases and 685,000 deaths reported worldwide in 2020 [1] . Clinically, this heterogeneous disease is classified into three main types based on estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status: hormone receptor (HR)-positive,  \nHuan-ping Zhang, Rui-yuan Jiang and Jia-yu Zhu are co-first authors.  \n* Ya-bing Zheng [zhengyb@zjcc.org.cn](zhengyb@zjcc.org.cn)  \n* Xiao-jia Wang [wxiaojia0803@163.com](wxiaojia0803@163.com)  \n1 Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou 310000, Zhejiang, China  \n2 Wenzhou Medical University, No. 270, Xueyuan West Road, Lucheng District, Wenzhou 325027, Zhejiang, China  \n3 Zhejiang Chinese Medical University, No. 548, Binwen Road, Binjiang District, Hangzhou 310000, Zhejiang, China  \nHER2-positive, and triple-negative breast cancers (TNBC)  \n[1] . Recent advances in endocrine and anti-HER2 therapies have improved the survival of patients with HR-positive and HER2-positive BC [1] . However, TNBC has a more aggressive and metastatic nature and a worse prognosis, and 46% of TNBC patients develop distant metastases, with a recurrence of 1.6–3.4 years [2] . Traditionally, TNBC was defined as a BC group lacking ER and PR expression, HER2 overexpression, or gene amplification. In 2011, Lyman et al. classified them into six subgroups: basal-like 1/2 (BL1/2), immunomodulatory (IM), mesenchymal (M), mesenchymal stem-like (MSL), and luminal androgen receptor (LAR) [3] .  \nNon-selective chemotherapy—represented by anthracyclines and taxanes—is the traditional treatment option for patients with locally recurrent inoperable or metastatic triple-negative breast cancer (mTNBC) . However, the efficacy of single or combination chemotherapy is poor, and the median overall survival (mOS) of patients with advanced TNBC rarely exceeds 12–18 months [3–5] . In addition, TNBC-targeted therapies include monoclonal antibody (mAb), antibody–drug conjugate (ADC), peptide–drug conjugate (PDC), and so on [6]. Recently, different immunotherapeutic modalities, including immune checkpoint blockade, vaccination, and adoptive cell transfer, have been extensively  \nstudied in the clinical setting of BC, particularly in pat","cbCaiozpQqB612cF","https://ap.wps.com/l/cbCaiozpQqB612cF","pdf",1645977,13,"English","# Abstract\n# Introduction\n## TNBC definition and molecular subtypes\n## Standard chemotherapy limitations and emerging targeted options\n## PI3K/AKT/mTOR pathway activation and regulation\n# PI3K/AKT/mTOR alterations in TNBC and therapeutic implications","[{\"question\":\"What makes triple-negative breast cancer (TNBC) clinically challenging?\",\"answer\":\"TNBC lacks ER, PR, and HER2, showing higher aggressiveness and a poor prognosis, with limited effective therapeutic strategies and frequent distant metastasis.\"},{\"question\":\"How does the PI3K/AKT/mTOR signaling pathway contribute to TNBC progression?\",\"answer\":\"Over-activation of PI3K/AKT/mTOR supports TNBC growth and survival, enhances proliferation and migration, and influences processes such as apoptosis inhibition, differentiation, and autophagy.\"},{\"question\":\"Which regulators are mentioned as key controls of the PI3K pathway in TNBC?\",\"answer\":\"PTEN negatively regulates PI3K by dephosphorylating PIP3 to PIP2 and silencing AKT signaling; additional phosphatase regulation is also described, affecting pathway activation.\"}]","PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer | PDF",1790021034,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f4292906c2a0f11aee73883ee57f9c3b.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b00ed719fc1e47a0ce4c9ad701e6932.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5ee0711560c0b0b6bdf4243ddae48007.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/faab94019e1d3256b33f0a5490e7fa67.webp",980,1301]